[1]
Feely RS, Larkin LM, Halter JB, Dengel DR. Chemical versus dual energy x-ray absorptiometry for detecting age-associated body compositional changes in male rats. Exp Gerontol 2000; 35: 417-27.
[2]
Seene T, Kaasik P, Riso EM. Review on aging, unloading and reloading: changes in skeletal muscle quantity and quality. Arch Gerontol Geriatr 2012; 54: 374-80.
[3]
Cederna PS, Asato H, Gu X, et al. Motor unit properties of nerve-intact extensor digitorum longus muscle grafts in young and old rats. J Gerontol A Biol Sci Med Sci 2001; 6: B254-8.
[4]
Sugiura M, Kanda K. Progress of age-related changes in properties of motor units in the gastrocnemius muscle of rats. J Neurophysiol 2004; 92: 1357-65.
[5]
Bruce KD, Byrne CD. The metabolic syndrome: common origins of a multifactorial disorder. Postgrad Med J 2009; 85: 614-21.
[6]
Seidell JC, Hautvast JG, Deurenberg P. Overweight: Fat distribution and health risks. Epidemiological observations A review. Infusionstherapie 1989; 16: 276-81.
[7]
Oliveira A, Rodriguez-Artalejo F, Severo M, Lopes C. Indices of central and peripheral body fat: association with non-fatal acute myocardial infarction. Int J Obes (Lond) 2010; 34: 733-41.
[8]
Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology 1997; 48: 1234-8.
[9]
Ruff RL, Martyn D, Gordon AM. Glucocorticoid-induced atrophy is not due to impaired excitability of rat muscle. Am J Physiol 1982; 243: E512-21.
[10]
Seene T. Turnover of skeletal muscle contractile proteins in glucocorticoid myopathy. J Steroid Biochem Mol Biol 1994; 50: 1-4.
[11]
Seene T, Kaasik P, Pehme A, Alev K, Riso E-M. The effect of glucocorticoids on the myosin heavy chain isoforms’ turnover in skeletal muscle. J Steroid Biochem Mol Biol 2003; 86: 201-6.
[12]
Chiu CS, Weber H, Adamski S, et al. Non-invasive muscle contraction assay to study rodent models of sarcopenia. BMC Musculoskelet Disord 2011; 12: 246.
[13]
Graves L, Lukert BP. Glucocorticoid-induced osteoporosis. Clin Rev Bone Miner Metab 2004; 2: 79-90.
[14]
Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18: 1319-28.
[15]
Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102: 274-82.
[16]
Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382-9.
[17]
Böcker W, El Khassawna T, Bauer N, et al. Short-term glucocorticoid treatment causes spinal osteoporosis in ovariectomized rats. Eur Spine J 2014; 23: 2437-48.
[18]
Attaix D, Mosoni L, Dardevet D, Combaret L, Mirand PP, Grizard J. Altered responses in skeletal muscle protein turnover during aging in anabolic and catabolic periods. Int J Biochem Cell Biol 2005; 37: 1962-73.
[19]
Dardevet D, Sornet C, Savary E, Debras E. Patureau-Mirand, Grizard J. Glucocorticoid effects on insulin- and IGF-1-regulated muscle protein metabolism during aging. J Endocrinol 1998; 156: 83-9.
[20]
Goldspink G, Harridge SD. Growth factors and muscle ageing. Exp Gerontol 2004; 39: 1433-8.
[21]
Seene T, Viru A. The catabolic effect of glucocorticoids on different types of skeletal muscle fibres and its dependence upon muscle activity and interaction with anabolic steroids. J Steroid Biochem 1982; 16: 349-52.
[22]
Seene T, Umnova M, Alev K, Pehme A. Effect of glucocorticoids on contractile apparatus of rat skeletal muscle. J Steroid Biochem 1988; 29: 313-7.
[23]
Albanese CV, Diessel E, Genant HK. Clinical applications of body composition measurements using DXA. J Clin Densitom 2003; 6: 75-85.
[24]
Stevenson KT, van Tets IG. Dual-energy X-ray absorptiometry (DXA) can accurately and non-destructively measure the body composition of small, free-living rodents. Physiol Biochem Zool 2008; 81: 373-82.
[25]
Faron KC. Cancer cachexia and fat. Muscle physiology. N Engl J Med 2011; 365: 565-7.
[26]
Kaasik P, Umnova M, Pehme A, et al. Ageing and dexamethasone associated sarcopenia: Peculiarities of regeneration. J Steroid Biochem Mol Biol 2007; 105: 85-90.
[27]
Seene T, Kaasik P. Role of myofibrillar protein catabolism in development of glucocorticoid myopathy: Aging and functional activity aspect. Metabolites 2016; 6: 15.
[28]
Ahtikoski AM, Riso EM, Koskinen SO, Risteli J, Takala TE. Regulation of type IV collagen gene expression and degradation in fast and muscle during dexamethasone treatment and exercise. Pflugers Arch – Eur j Physiol 2003; 448: 123-30.
[29]
Ma K, Mallidis C, Bhasin S, et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 2003; 285: E363-71.
[30]
Auclair D, Garrel DR, Chaouki Zerouala A, Ferland LH. Activation of the ubiquitin pathway in rat skeletal muscle by catabolic doses of glucocorticoids. Am J Physiol 1997; 272: 1007-16.
[31]
Singleton JR, Baker BL, Thorburn A. Dexamethasone inhibits insulin-like growth factor signalling and potentiates myoblast apoptosis. Endocrinology 2000; 141: 2945-50.
[32]
Carballo-Jane E, Pandit S, Santoro JS, et al. Skeletal muscle: a dual system to measure glucocorticoid-dependent transactivation and transrepression of gene regulation. J Steroid Biochem Mol Biol 2004; 88: 191-201.
[33]
Moore DR, Tang JE, Burd NA, Rerecich T, Tarnopolsky MA, Phillips SM. Differential stimulation of myofibrillar and sarcoplasmic protein synthesis with protein ingestion at rest and after resistance exercise. J Physiol 2009; 587: 897-904.
[34]
Moore DR, Atherton PJ, Rennie MJ, Tarnopolsky MA, Phillips SM. Resistance exercise enhances mTOR and MAPK signalling in human muscle over that seen at rest after bolus protein ingestion. Acta Physiol 2011; 201: 365-72.
38
5